GlobeNewswire: Curis, Inc. Contains the last 10 of 189 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:35:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/12/01/1216117/0/en/Curis-Announces-Upcoming-Presentation-at-the-American-Society-of-Hematology-59th-Annual-Meeting-Exposition.html?f=22&fvtc=4&fvtv=14316Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition2017-12-01T12:00:00Z<![CDATA[LEXINGTON, Mass., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced an upcoming presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 9, 2017, in Atlanta. This presentation will provide an analysis of results from the Phase 2 trial of CUDC-907.]]>https://www.globenewswire.com/news-release/2017/11/07/1176319/0/en/Curis-Reports-Third-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=14316Curis Reports Third Quarter 2017 Financial Results2017-11-07T12:00:00Z<![CDATA[-- Management to host conference call today at 8:30 a.m. EST -- -- Management to host conference call today at 8:30 a.m. EST --]]>https://www.globenewswire.com/news-release/2017/11/03/1174402/0/en/Curis-to-Present-at-the-Society-for-Immunotherapy-of-Cancer-32nd-Annual-Meeting-and-the-Cowen-IO-NEXT-Summit.html?f=22&fvtc=4&fvtv=14316Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit2017-11-03T11:00:00Z<![CDATA[LEXINGTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting and a presentation by Ali Fattey, CEO, as part of an analyst-moderated fireside chat at the Cowen IO NEXT Summit. The presentations will take place Nov. 10, 2017, at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland.]]>https://www.globenewswire.com/news-release/2017/11/01/1172092/0/en/Curis-to-Release-Third-Quarter-2017-Financial-Results-and-Hold-Conference-Call-on-November-7-2017.html?f=22&fvtc=4&fvtv=14316Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 20172017-11-01T11:00:00Z<![CDATA[LEXINGTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its third quarter 2017 financial results on Tuesday, November 7, 2017, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST.]]>https://www.globenewswire.com/news-release/2017/09/22/1131606/0/en/Curis-to-Present-at-the-Cantor-Fitzgerald-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=14316Curis to Present at the Cantor Fitzgerald Global Healthcare Conference2017-09-22T15:54:01Z<![CDATA[LEXINGTON, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Ali Fattaey, Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, Sept. 25, 2017, at 3:35 p.m. EDT in New York.]]>https://www.globenewswire.com/news-release/2017/09/14/1121069/0/en/Curis-Announces-Pricing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=14316Curis Announces Pricing of Public Offering of Common Stock2017-09-14T11:00:00Z<![CDATA[LEXINGTON, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock (the “Offering”). The Offering is expected to close on or about September 18, 2017, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2017/09/13/1120484/0/en/Curis-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=14316Curis Announces Proposed Public Offering of Common Stock2017-09-13T20:04:35Z<![CDATA[LEXINGTON, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced its intention to offer and sell up to 20 million shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement.]]>https://www.globenewswire.com/news-release/2017/09/11/1117304/0/en/Curis-and-Aurigene-Announce-CA-170-Program-Update-Following-Data-Presented-at-ESMO-2017.html?f=22&fvtc=4&fvtv=14316Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 20172017-09-11T08:00:00Z<![CDATA[-- Results from 34 Patients Demonstrate Positive Safety Profile and Support Decision to Expand Development ---- Aurigene and Curis Plan Clinical Trial of CA-170 in India --]]>https://www.globenewswire.com/news-release/2017/09/06/1108237/0/en/Curis-to-Present-at-the-Baird-2017-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=14316Curis to Present at the Baird 2017 Global Healthcare Conference2017-09-06T11:00:00Z<![CDATA[LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Baird 2017 Global Healthcare Conference on September 6 at 10:15 a.m. EDT in New York.]]>https://www.globenewswire.com/news-release/2017/08/31/1106035/0/en/Curis-Announces-CA-170-Poster-Presentation-at-ESMO-2017-Congress.html?f=22&fvtc=4&fvtv=14316Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress2017-08-31T11:00:00Z<![CDATA[LEXINGTON, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a trial-in-progress poster describing preliminary clinical data from the dose escalation stage of CA-170 Phase 1 clinical trial at the European Society for Medical Oncology (ESMO) 2017 Congress. The conference will take place September 8-12 in Madrid. CA-170, an oral small molecule targeting the immune checkpoints PDL1 and VISTA, is in development for the treatment of patients with advanced solid tumors or lymphomas.]]>